The price of Hemgenix, which easily surpasses Novartis' Zolgensma gene therapy for spinal muscular atrophy (SMA), which costs close to $2 million per dose and is also a single-dose medication, makes it the most expensive medication in the world, according to a study cited by the National Library of Medicine. 

• The cost of the new treatment, like that of the majority of American medications, will primarily be covered by insurers, not by the patient, both through private plans and public programmes.
• The price of Hemgenix, which easily surpasses Novartis' Zolgensma gene therapy for spinal muscular atrophy (SMA), which costs close to $2 million per dose and is also a single-dose medication, makes it the most expensive medication in the world, according to a study cited by the National Library of Medicine. 
• The cost of the new treatment, like that of the majority of American medications, will primarily be covered by insurers, not by the patient, both through private plans and public programmes.
• The Pennsylvania-based pharmaceutical company CSL Behring published the $3.5 million price tag immediately after the FDA granted its approval, claiming that the medicine would ultimately lower healthcare costs because patients would experience fewer bleeding events and require fewer clotting therapies.